North Dakota
Requires Coverage of Comprehensive Biomarker Testing
No
Highlighted Disparity
Indigenous peoples in North Dakota are most likely to be diagnosed with lung cancer
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases in North Dakota is 54.3 and not significantly different than the national rate of 52.8.
- It ranks 26th among all states, placing it in the average tier.
- Over the last five years, the rate of new cases in North Dakota improved by 24%.
- In 2022, the most recent year of data available for this report, the COVID-19 pandemic continued to disrupt access to medical care, including delays and reductions in cancer diagnoses and screening. This led to a decline in incidence rates for most cancers, including lung cancer, and should not be interpreted as a reduction in the underlying cancer burden.
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer (the survival rate) in North Dakota is 31.0%, which is not significantly different than the national rate of 29.7%.
- It ranks 15th among the 39 states with survival data, placing it in the average tier.
- Over the last five years, the survival rate in North Dakota improved by 30%.
Early Diagnosis:
- In North Dakota, 32.1% of cases are caught at an early stage, which is significantly higher than the national rate of 28.1%.
- It ranks 6th among the 50 states with data on diagnosis at an early stage, placing it in the above average tier.
- Over the last five years, the early diagnosis rate in North Dakota improved by 36%.
Lung Cancer Treatment
Biomarker Coverage:
- North Dakota has yet to require any insurance coverage of comprehensive biomarker testing, including for lung cancer, as of August 2025.
Surgical Treatment:
- North Dakota ranked 33rd (out of the 49 states with available data) with 17.7% of cases undergoing surgery as part of the first course of treatment.
- This is significantly lower than the national rate of 20.7% and puts North Dakota in the below average tier.
- Over the last five years, the percent of cases undergoing surgery in North Dakota did not change significantly.
No Treatment:
- North Dakota ranked 3rd (out of the 49 states with available data) with 14.8% of cases not receiving any treatment.
- This is significantly lower than the national rate of 21.0% and puts North Dakota in the top tier.
- Over the last five years, the percent of cases receiving no treatment in North Dakota did not change significantly.
Screening
Screening for High Risk:
- In North Dakota, 21.1% of those at high risk were screened, which was not significantly different than the national rate of 18.2%.
- It ranks 15th among all states, placing it in the above average tier.
- Screening rates in this year’s report have been updated to correct an error in the data source and should not be compared to previous reports.
Prevention
Tobacco Use:
- The 2023 smoking rate in North Dakota is 13.3% and significantly higher than the national rate of 11.4%.
- It ranks 31st among all states, placing it in the below average tier.
Radon Exposure:
- In North Dakota, 58.0% of radon test results were at or above the action level recommended by EPA.
- It ranks 50th among all states, placing it in the bottom tier.
Racial & Ethnic Disparities
Black individuals:
- Lung cancer rates are not available for Black individuals in North Dakota due to too few cases over the time period to allow for accurate analysis.
Latino individuals:
- Lung cancer rates are not available for Latino individuals in North Dakota due to too few cases over the time period to allow for accurate analysis.
Asian or Pacific Islander individuals:
- Lung cancer rates are not available for Asian or Pacific Islander individuals in North Dakota due to too few cases over the time period to allow for accurate analysis.
Indigenous Peoples:
- The rate of new lung cancer cases is 132.8 per 100,000 population among Indigenous peoples (American Indians/Alaska Natives) in North Dakota, significantly higher than the rate of 39.8 among Indigenous Peoples nationally, and significantly higher than the rate of 52.5 among white individuals in North Dakota.
- State-level survival rates are not available for Indigenous Peoples at this time. Nationally, the five-year survival rate among Indigenous Peoples is 22.3% and not significantly different than the rate of 25.0% among white individuals.
- 27.4% of lung cancer cases are diagnosed at an early stage among Indigenous peoples (American Indians/Alaska Natives) in North Dakota, not significantly different than the rate of 25.2% among Indigenous peoples (American Indians/Alaska Natives) nationally, and not significantly different than the rate of 32.7% among white individuals in North Dakota.
- 14.9% of Indigenous peoples (American Indians/Alaska Natives) with lung cancer in North Dakota underwent surgery, not significantly different than the rate of 15.6% among Indigenous peoples (American Indians/Alaska Natives) nationally, and not significantly different than the rate of 17.8% among white individuals in North Dakota.
- 19.6% of Indigenous peoples (American Indians/Alaska Natives) with lung cancer in North Dakota did not receive any treatment, not significantly different than the rate of 25.0% among Indigenous peoples (American Indians/Alaska Natives) nationally, and not significantly different than the rate of 14.4% among white individuals in North Dakota.
Summary
Despite the early diagnosis rate in North Dakota falling into the above average tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
North Dakota has yet to require any insurance coverage of comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
North Dakota falls into the top tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: October 29, 2025
